Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetesCompanies: Boehringer IngelheimCompany announcement – No. 52 / 2026
- Boehringer Ingelheim and WHO Foundation launch global collaboration to close the gap in obesity and metabolic healthCompanies: Boehringer IngelheimIngelheim, Germany - Boehringer Ingelheim and the WHO Foundation today announced a three-year collaboration to accelerate progress on obesity and its related metabolic conditions in resource-limited settings.